Genentech’s Perjeta Combination Therapy Effective for Aggressive Breast Cancer

Genentech’s Perjeta Combination Therapy Effective for Aggressive Breast Cancer
shutterstock_158445182Newly released data from Genentech's international phase 3 CLEOPATRA study demonstrates the efficacy of Perjeta treatment in patients with previously untreated HER2-positive metastatic breast cancer. Patient survival was extended by 15.7 months to almost five years, which is remarkable for aggressive breast cancer. "Adding Perjeta to treatment with Herceptin and chemotherapy resulted in the longest survival observed to date in a clinical study of people with HER2-positive metastatic breast cancer," said Sandra Horning, MD, chief medical officer and head of Global Product Development, in a news release from the company. The findings were presented at the Presidential Symposium at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid. CLEOPATRA, or "Clinical Evaluation of Pertuzumab and Trastuzumab," evaluated 808 patients with recurrent metastatic HER2-positive breast cancer using the primary outcome of progression-free survival assessed by an independent review committee. Treatment consisted of either Perjeta, Herceptin, and docetaxel chemotherapy or pla
Subscribe or to access all post and page content.